GLGuodong Li

Guodong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guodong Li has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy

    by Xiaoshuang Niu, Menghan Wu, Guodong Li, Xiuman Zhou, Wenpeng Cao, Wenjie Zhai, Aijun Wu, Xiaowen Zhou, Shengzhe Jin, Guanyu Chen, et al.


  • Open Access

    A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting

    by Ying Zhou, Shuyi Song, Baomei Yuan, Yahong Wu, Yanfeng Gao, Guangming Wan, Guodong Li

    Immune checkpoint inhibitors (ICIs) are changing all aspects of malignant tumour therapy as an immunotherapy subverter in oncology. However, the current ICIs might induce systemic immune activation in other tissues and organs since they are not tumour-specific, causing the immune system to attack some normal tissues and organs of the human body. The toxicity can also amplify greatly although combined immunotherapy for cancer has increased the curative efficacy. The LC4 peptide was modified to improve its tumour-targeting ability and reduce peripheral immune system activation, which was obtained through phage display peptide library screening and could block the CTLA-4/CD80 interaction. The LC4 peptide as a result, like other ICIs, exerts anti-tumour effects by refreshing T cell function, and also activates the peripheral immune system. We used the PLGLAG peptide as a linker at the C-terminal of LC4 to connect with a tumour-targeting peptide RGD to increase the tumour tissue targeting ability, and obtain LC4-PLG-RGD. Further experiments demonstrated that the anti-tumour LC4-PLG-RGD activity was better than LC4 in vivo, and the ability to activate the peripheral immune system was weakened. In conclusion, LC4-PLG-RGD can increase the ICIs tumour-targeting and reduce excessive peripheral tissue immune activation, thereby reducing the side effects of ICIs, while increasing their anti-tumour efficacy. This study confirmed that enhanced ICI tumour targeting can effectively reduce immune-related adverse reaction occurrence.


  • Open Access

    4-Hydroxyisoleucine inhibits tumor growth by triggering endoplasmic reticulum stress and autophagy

    by Peng Li, Yonghui Yang, Lu Qiu, Guangming Wan, Baomei Yuan, Yahong Wu, Yanfeng Gao, Guodong Li

  • Open Access

    4-Hydroxyisoleucine Alleviates Macrophage-Related Chronic Inflammation and Metabolic Syndrome in Mice Fed a High-Fat Diet

    by Jiali Yang, Yunhui Ran, Yonghui Yang, Shuyi Song, Yahong Wu, Yuanming Qi, Yanfeng Gao, Guodong Li

    In obesity, macrophages and other immune cells accumulate in organs affected by insulin, leading to chronic inflammation and insulin resistance. 4-Hydroxyisoleucine (4-HIL) is a non-protein amino acid found in fenugreek seeds. 4-HIL enhances insulin sensitivity, but its mechanism is still unclear. In this study, 4-HIL intervention reduced weight gain, liver steatosis, and dyslipidemia; moreover, it increased systemic insulin sensitivity and improved insulin resistance in mice. Importantly, after administration, the accumulation of M1 like CD11c+ macrophages and inflammation in the liver and adipose tissue were reduced in the mice. 4-HIL also reduced the proportion of CD11c+ macrophages among bone marrow-derived macrophages, which were induced in vitro. These observations demonstrate a new role of 4-HIL in insulin resistance in hepatocytes and adipocytes. 4-HIL inhibits obesity-related insulin resistance by reducing inflammation and regulating the state of M1/M2 macrophages.


  • Open Access

    Identification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis

    by Yan Lin, Yu Dong, Yanfeng Gao, Ranran Shi, Yubing Li, Xiuman Zhou, Wenwen Liu, Guodong Li, Yuanming Qi, Yahong Wu

    Tuberculosis is the worlds most deadly infectious disease, with 10 million people falling ill and 1.5 million people dying from the disease every year. With the increasing number of drug-resistant Mycobacterium tuberculosis (MTB) strains and prevalence of coinfection of MTB with human immunodeficiency virus, many challenges remain in the prevention and treatment of tuberculosis. Therefore, the development of safe and effective tuberculosis vaccines is an urgent issue. In this study, we identified cytotoxic T lymphocyte epitopes on drug resistance-associated membrane protein efflux pumps of MTB, the ATP-binding cassette and the major facilitator superfamilies. First, three online software were used to predict HLA-A2-restricted epitopes. Then, the candidate epitopes were confirmed with the T2A2 cell binding affinity and peptide/MHC (pMHC) complex stability assays and in vitro immune activity experiments. Two drug-resistant T lymphocyte epitopes, designated Rv1218c-p24 and Rv2477c-p182, were selected, and their immunogenic activities studied in vivo in genetically engineered mice. The immune activities of these two epitopes were improved with the help of complete Freunds adjuvant (CFA). The epitopes identified here provide a foundation for the diagnosis and treatment of patients infected with drug resistant and the future development of a multiepitope vaccine.


  • Open Access

    Function expansion of antitumor transcriptional activator NFE2L1 by the original discovery of its non-transcription factor activity

    by Qiu Lu, Yang Qiufang, Li Peng, Zhou Xiaowen, Yang Yonghui, Zhou Xiuman, Gou Shanshan, Zhai Wenjie, Li Guodong, Ren Yonggang, et al.

    Antitumor transcription activator NFE2L1, with the functions to regulate redox homeostasis, protein turnover, and material metabolism, plays an important role in embryonic development and specialization of tissue and organ functions. Deficiency of NFE2L1 gene in different regions yields distinct phenotypes, suggesting that NFE2L1 may have a transcription factor-independent function. Here we originally discovered the non-transcription factor activity of NFE2L1 by constructing a truncated protein-NFE2L1 ΔC without 152 aa at the C-terminus which lost the transcription factor activity. The regulation of NFE2L1 on redox homeostasis, proteasome function, and immune response mainly depends on its transcription activator function in nucleus, while the regulation on metabolism, ribosome function, and canceration is germanely to its non-transcription factor activity in cytoplasm. Surprisingly, the results indicated the tumor suppressive effect of NFE2L1 by repression of Wnt/β-catenin signaling in a non-transcription factor manner, indicating the potential value of NFE2L1 as a therapeutic target in clinical cancer treatment independent of its transcription factor activity. Our observations reveal the non-transcription factor activity of NFE2L1 for the first time, and lay foundation for the basic and applied research of NFE2L1.


  • The dual effects of a novel peptibody on angiogenesis inhibition and M2 macrophage polarization on sarcoma

    by Xiaoqing Zhu, Jiali Yang, Yanfeng Gao, Chunjing Wu, Lili Yi, Guodong Li, Yuanming Qi


  • Open Access

    Screening and identification of the tumor‐associated antigen CK10, a novel potential liver cancer marker

    by Zhaoyu Zhu, Zheng Liu, Yuchun Liu, Chunyan Wang, Ruyu Li, Hui Liu, Baohua Gu, Guodong Li, Shoutao Zhang

    Hepatocellular carcinoma (HCC) is a malignancy that is associated with high mortality rates in Asia. These tumors are highly invasive and their etiology is frequently unknown. Thus, most patients are diagnosed in the middle and late stages of the disease, and thus do not have sufficient time for therapy. Therefore, it is essential to study the early diagnosis and treatment of HCC; in this regard, the study of tumor‐associated antigens has received much attention. Here, antigens from the human primary HCC cell line, QGY‐7703, were used to immunize mice in order to prepare monoclonal antibodies. The specific antigen recognized by antibody 11C3 was purified from total protein lysates of QGY‐7703 by immunoaffinity chromatography. The validity of the candidate antigen as a new HCC‐associated marker was tested using SDS/PAGE, western blot, HPLC‐ESI‐MS/MS, and RT‐qPCR. Our results showed that the levels of CK10 in HCC‐derived cell lines were significantly higher than those in normal liver cells. Thus, we suggest that CK10 may be involved in the formation and development of HCC, and may be a therapeutically targetable tumor‐associated antigen.


  • Open Access

    The extracellular death factor (EDF) protects Escherichia coli by scavenging hydroxyl radicals induced by bactericidal antibiotics

    by Zhongyi Yan, Guodong Li, Yanfeng Gao, Wenjie Zhai, Yuanming Qi, Mingxia Zhai

    The newly discovered extracellular death factor (EDF) is a pentapeptide with the sequence NNWNN in Escherichia coli. It was reported that it participated in the cell death process mediated by toxin-antitoxin system mazEF. Reactive oxygen species (ROS) are recently considered as common factors for bactericidal antibiotics-mediated cell death. Previous study indicated that EDF could scavenge hydroxyl radicals and might act as a signal molecule with dual effects, “death” and “survival”. But the structure-activity relationship of EDF and the effects of EDF on the activity of antibiotics remain unclear. In the present study, our results indicated that tryptophan could be the key residue to the hydroxyl radicals-scavenging activity of EDF, and EDF could protect Escherichia coli from killing by bactericidal antibiotics, but not by DNA-damaging or bacteriostatic antibiotics. Our results could provide novel evidence to understand the role of EDF in drug-resistance.